Abstract
Introduction Out-of-hospital mortality in coronary artery disease (CAD) is particularly high and established adverse event prediction tools are yet to be available. Our study aimed to investigate whether precision phenotyping can be performed using routine laboratory parameters for the prediction of out-of-hospital survival in a CAD population treated by percutaneous coronary intervention (PCI).
Materials and methods All patients treated by PCI and discharged alive in a tertiary center between January 2016 – December 2022 that have been included prospectively in the local registry were analyzed. 115 parameters from the PCI registry and 266 parameters derived from routine laboratory testing were used. An extreme gradient-boosted decision tree machine learning (ML) algorithm was trained and used to predict all-cause and cardiovascular-cause survival.
Results A total of 7186 PCI hospitalizations for 5797 patients were included with more than 610.000 laboratory values. All-cause and cardiovascular cause mortality was 17.5% and 12.2%, respectively, during a median follow-up time of 1454 (687 – 2072) days. The integrated area under the receiver operator characteristic curve for prediction of all-cause and cardiovascular cause mortality by the ML on the validation dataset was 0.844 and 0.837, respectively (all p<0.001). The integrated area under the precision-recall curve for prediction of all-cause and cardiovascular cause mortality by the ML on the validation dataset was 0.647 and 0.589, respectively (all p<0.001).
Conclusion Precise survival prediction in CAD can be achieved using routine laboratory parameters. ML outperformed clinical risk scores in predicting out-of-hospital mortality in a prospective all-comers PCI population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethical committee of our institution (decision number 8646 from 22 December 2015 approved by the Ethical Committee of the Emergency Institute for Cardiovascular Diseases and Transplantation of Târgu Mureş).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This research received no funding.